Scientists hunt for genetic clues to deadly heart side effect of cancer drugs
NCT ID NCT06734689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find genetic differences that make some cancer patients more likely to develop a rare but life-threatening heart inflammation (myocarditis) from immune checkpoint inhibitors. Researchers will compare the DNA of 100 patients who had this side effect with 400 who did not. The goal is to identify risk genes and build a score to predict who is most at risk, helping doctors make safer treatment choices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Pitié Salpêtrière
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
- Money worries and cancer: can talking about both ease the burden?
- Digital navigator aims to cut financial toxicity for young adults with cancer
- Can a simple checklist boost recovery after cancer surgery?
- Leftover blood samples could unlock new medical discoveries